Current knowledge suggests that hypertension is in part mediated by immune mechanisms. Both IL-23 and IL-17 are upregulated in several experimental hypertensive rodent models, as well as in hypertensive humans in observational studies. Recent preclinical studies have shown that either IL-23 or IL-17A treatment induce blood pressure elevation. However, the IL-23/IL-17 axis has not been a major therapeutic target in hypertension, unlike in other autoimmune diseases. In this review, we summarize current knowledge on the role of these cytokines in immune mechanisms contributing to hypertension, and discuss the potential of IL-23/IL-17-targeted therapy for treatment of hypertension.
Research Abstract
Research Department
Research Journal
Cardiovascular Research
Research Member
Research Publisher
NULL
Research Rank
1
Research Vol
NULL
Research Website
https://academic.oup.com/cardiovascres/advance-article/doi/10.1093/cvr/cvaa257/5900262?guestAccessKey=a302e297-4f36-4c47-8f8f-a7ba21a1047c
Research Year
2020
Research Pages
NULL